As a result, centrosome declustering drugs comprise a highly promising class of nontoxic, cancer-cell-selective therapeutic agents [129] that ought to be used in any scenario wherein hypoxic conditions are likely to occur including in combination with AR-targeting therapies for TNBC. The gene discussed is AR; the disease is cancer.